Anti-hepatic fibrosis drug composite

Abstract

The invention relates to an anti-hepatic fibrosis drug composite. The anti-hepatic fibrosis drug composite is characterized by comprising the following crude drugs in parts by weight: 5-15 parts of artemisia anomala, 10-20 parts of geranium wilfordii, 1-5 parts of leeches and 1-5 parts of Zhechong. The anti-hepatic fibrosis drug composite disclosed by the invention can be used for preparing the artemisia anomala, the geranium wilfordii, the leeches and the zhechong into a compound according to a traditional Chinese medicine theory, achieves the purpose of anti-hepatic fibrosis through the synergistic action of the drugs on the aspects of anti-inflammation, anti-necrosis, hepatic cells protection, and the like and has the advantages of low price and easiness for popularization.

Description

technical field [0001] The invention relates to a pharmaceutical composition for resisting liver fibrosis, in particular to a traditional Chinese medicine compound with good curative effect for resisting liver fibrosis. Background technique [0002] Liver fibrosis refers to the pathological process of abnormal proliferation of intrahepatic connective tissue caused by various pathogenic factors, leading to excessive precipitation of diffuse extracellular matrix in the liver. It is not an independent disease, and many chronic liver diseases can cause liver fibrosis. my country is a high-incidence area of ​​viral hepatitis. Viral hepatitis is a common cause of liver fibrosis and cirrhosis. There are tens of millions of patients with chronic hepatitis, and about 1 / 10 to 1 / 3 of them can develop into cirrhosis. Liver fibrosis is the pathological basis of liver cirrhosis caused by various etiologies. In recent years, with the rapid development and application of medical molecular...

AI Technical Summary

Problems solved by technology

Most treatments are still in the experimental research stage

Images